Recently, this EGFR-targeted α-emitter bearing radiopharmaceutical has been applied in a pilot study for patients with bladder carcinoma in situ instead of the usual cystectomy (Autenrieth et al., 2018). The gene discussed is EGFR; the disease is bladder carcinoma in situ.